Day One Biopharmaceuticals (NASDAQ:DAWN) Posts Earnings Results, Beats Expectations By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings results on Wednesday. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58, Briefing.com reports. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the previous year, the business earned ($0.54) EPS.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock traded up $0.17 during trading hours on Thursday, reaching $14.64. The company had a trading volume of 2,053,830 shares, compared to its average volume of 926,202. Day One Biopharmaceuticals has a 12-month low of $10.90 and a 12-month high of $18.07. The company has a 50-day moving average price of $14.16 and a 200 day moving average price of $14.38. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -7.42 and a beta of -1.51.

Analyst Ratings Changes

DAWN has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Finally, Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,633 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $36,862.00. Following the sale, the chief financial officer now owns 232,485 shares of the company’s stock, valued at $3,254,790. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,633 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $36,862.00. Following the completion of the sale, the chief financial officer now owns 232,485 shares in the company, valued at approximately $3,254,790. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,748 shares of company stock worth $689,072. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.